Compare III & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | III | ACIU |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | Switzerland |
| Employees | 1500 | 122 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.7M | 221.9M |
| IPO Year | 2006 | 2015 |
| Metric | III | ACIU |
|---|---|---|
| Price | $3.99 | $2.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 257.8K | 256.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.46% | N/A |
| EPS Growth | ★ 216.67 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $192,745,000.00 | N/A |
| Revenue This Year | $3.85 | $706.75 |
| Revenue Next Year | $4.34 | $321.13 |
| P/E Ratio | $81.50 | ★ N/A |
| Revenue Growth | ★ 4.51 | N/A |
| 52 Week Low | $3.74 | $2.03 |
| 52 Week High | $6.45 | $4.00 |
| Indicator | III | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 44.73 | 36.96 |
| Support Level | $3.88 | $2.15 |
| Resistance Level | $4.33 | $2.66 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 22.06 | 11.11 |
Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.